Market News

Unstoppable Growth: Bolt Biotherapeutics Surpasses Analyst Expectations for Q4 2023

by Ron Finklestien

Published On: March 22, 2024 12:45 am

Beating the Odds:

BOLT stock - BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023

Source: iQoncept / Shutterstock

Bolt Biotherapeutics (NASDAQ:BOLT) recently announced its Q4 2023 results.

Bolt Biotherapeutics exceeded expectations by reporting earnings per share of -47 cents, beating the analyst forecast of -48 cents.
The company achieved a revenue of $2.09 million, surpassing the anticipated $1.71 million by a remarkable 22.16%.

InvestorPlace Earnings uses data from TradeSmith to automate coverage of quarterly earnings. This approach provides key insights into metrics like earnings per share and revenue, allowing investors to compare a company’s performance against analyst estimates. By delivering this information promptly and accurately, we strive to keep our readers informed of the latest financial developments. To report any discrepancies, please contact us at [email protected].

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/bolt-stock-earnings-bolt-biotherapeutics-for-q4-of-2023/.